Rare Disease and Orphan Drug Development

There are 7,000 rare diseases impacting 350 million patients worldwide, yet only 300 of these diseases have approved treatments. This gap, impacting 95% of those suffering from rare diseases, represents a huge unmet medical need. Modeling and simulation approaches are not only ideal for the development of drugs for rare diseases, but are encouraged by regulators.

Read More
Topics:

Model-based development of gemcabene, a new lipid-altering agent

The purpose of this study was to evaluate the value of model-based, quantitative decision making during the development of gemcabene, a novel lipid-altering agent. The decisions were driven by a model of the likely clinical profile of gemcabene in comparison with its competitors, such as 3-hydroxymethylglutaryl coenzyme A reductase inhibitors (statins), the cholesterol absorption inhibitor […]

Read More
Topics:

Learning from Failure: Leveraging Biosimulation for Pediatric Drug Development Success

The high rate of trial failures, increasing regulatory demands, and ethical imperatives all require a reexamination of the current approach to pediatric drug development. Biosimulation is a proven approach that will help optimize trial design and inform the drug label. This approach can support global regulatory strategies that increase the likelihood of success for pediatric drug development programs.

Read More
Topics:

Conducting Virtual Trials Using PBPK to Drive More Precise Label Claims

Biosimulation technology is revolutionizing the way in which the pharmaceutical industry does business and how the regulators are reviewing new drug approvals. Biosimulation leverages both empirical analysis of clinical data and mechanistic in silico approaches. The latter approach encompasses both in vitro-in vivo extrapolation (IVIVE) and physiologically-based pharmacokinetic modeling and simulation (PBPK M&S).

Read More
Topics:

Modeling and Simulation Supports Post-Approval Commitment in Oncology

Modeling strategy provided sponsor with rational basis for quantifying efficacy benefit of approved dose to avoid Phase IV trial, saving $6-20 Million and redirecting resources towards other programs. A global biopharmaceutical company was seeking to fulfill a post-approval commitment to regulatory authorities for its currently approved oncology drug. Regulatory approval in the given indication was […]

Read More
Topics:

Modeling and Simulation Supports Competitve Product Profile Assessment

Modeling strategy provided sponsor timely and compelling support for positive efficacy signal of in-licensing candidate, helping to secure $23 Million financing round and advance compound to Phase IIB. A specialty pharmaceutical company was seeking to provide rapid, quantitative support to fund its in-licensing strategy for an oral Type 2 anti-diabetic agent. Limited data from a […]

Read More
Topics:

Modeling and Simulation Supports Competitive Dose

Assessment and go/no go decision in Alzheimer’s Disease modeling strategy provided sponsor with rational basis for product profile evaluation to avoid placing non-competitive dose into Phase III, saving $85 Million and redirecting resources towards other programs A global pharmaceutical company was seeking to advance its drug candidate, indicated for symptomatic treatment for Alzheimer’s Disease (AD), […]

Read More
Topics:

Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review.

Physiologically based pharmacokinetic (PBPK) modeling and simulation is a tool that can help predict the pharmacokinetics of drugs in humans and evaluate the effects of intrinsic (e.g., organ dysfunction, age, genetics) and extrinsic (e.g., drug-drug interactions) factors, alone or in combinations, on drug exposure. The use of this tool is increasing at all stages of the drug […]

Read More
Topics:

How to Optimize Your Drug Label Using Biosimulation Methodology

While biosimulation has been an important element in drug development for some time, its impact over the past 18 months with regard to label optimization has been profound. Specifically, FDA’s acceptance of Physiologically-Based Pharmacokinetic (PBPK) modeling and simulation has impacted key label elements in more than a dozen cases, driving down R&D costs and timelines, […]

Read More
Topics:

Connecting Phoenix to your PK/PD Data Analysis and Reporting Workflow

The pharmaceutical industry is rapidly integrating systems, software, and knowledge across many disciplines. What were once stand-alone systems are now part of a larger workflow that moves research from the bench to the clinic. Pharmacokinetic (PK) and pharmacodynamic (PD) analysis is an essential part of that workflow. Certara’s Phoenix platform enables users to seamlessly integrate […]

Read More
Topics:

Improve Your Success Rate in Costly Bioequivalence Studies with IVIVC

Are you looking to support a bio waver for changes in manufacturing site, raw material suppliers and minor changes in formulation with Level A IVIVC? In this webinar, Dr. Terry Shepard of the Medicines and Healthcare product Regulatory Agency (MHRA) discussed the regulatory applications of IVIVC including the specification settings and biowaivers. She also explained […]

Read More
Topics:
Learn More
LinkedIn